Peer Review Committee for Tumor Biology and Genomics (TBG)

Areas reviewed: In vivo tumor models, oncogenes and tumor suppressor genes in vivo, gene target validation, drug efficacy testing, human genetics/genomics, pharmacogenetics, pharmacogenomics, genetic risk, genotype to phenotype, gene therapy testing, and biomarker identification/development.

Amanda Toland, PhD, Chair
The Ohio State University
Columbus, OH

Jonathan Brody, PhD, Vice-Chair
Thomas Jefferson University
Philadelphia, PA

Ron Bose, MD, PhD
Washington University
St. Louis, MO

Kevin M. Brown, PhD
National Cancer Institute
Bethesda, MD

Mark Chiang, MD, PhD
University of Michigan
Ann Arbor, MI

Deborah Cornwall, Stakeholder
Marshfield Hills, MA

Dan G. Duda, PhD
Massachusetts General Hospital
Boston, MA

Michael E. Engel, MD, PhD
University of Utah
Salt Lake City, UT

Rani E. George, MD, PhD
Harvard Medical School
Boston, MA

Scott A. Gerber, PhD
Dartmouth College
Lebanon, NH

Lata Jayaraman, PhD
Seres Therapeutics
Cambridge, MA

Sandra McAllister, PhD
Brigham and Women’s Hospital
Boston, MA

Nicholas Mitsiades, MD, PhD
Baylor College of Medicine
Houston, TX

Kristy L. Richards, PhD, MD
Cornell University
Ithaca, NY  14853-6401

Alejandro Sweet-Cordero, MD
University of California
San Francisco, CA

Kathryn A. Wikenheiser-Brokamp, MD, PhD
Children’s Hospital Medical Center
Cincinnati, OH

Christopher Willey, MD, PhD
University of Alabama
Birmingham, AL